4D Molecular Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 10, 2021 and accepted by EDGAR at Nov 10, 2021, 21:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $1.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $17.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-07-01 to 2021-09-30 | $15.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-01-01 to 2021-09-30 | $43.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$22.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | −$46.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-07-01 to 2021-09-30 | −$22.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | −$46.2m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | −$47.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-09-30 | $4.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-09-30 | $91.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $165.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $240.6m | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $11.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $16.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-09-30 | $224.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-21-004086. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.